8 news items
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable NiagenĀ® (Patented Nicotinamide Riboside Chloride or NRC)
CDXC
13 Jun 24
, safety, and efficacy are unknown. Unlike the NAD+ molecule itself, or other common
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
CDXC
7 Jun 24
the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
CDXC
4 Jun 24
-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
CDXC
23 May 24
in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator
ChromaDex's NiagenĀ® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
CDXC
22 May 24
the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship
ukp k3kd2wsh
CDXC
30 Apr 24
the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship
k56um8cnqhmyprqj253wlr0sq8dy4r vyg
CDXC
24 Apr 24
in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient
ouc6t8q4z4jzj4ankx rc1j270ga0
CDXC
26 Mar 24
.
"We hold Tru Niagen to the highest quality, safety, transparency, and scientific standards
- Prev
- 1
- Next